Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (211-220 of 446) with videos related to

Pageof 45
Sort By:
American Journal of Hematology|July 28, 2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapiesNeil Majithia, S Vincent Rajkumar, Martha Q Lacy, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Blood Cancer Journal|January 16, 2024
Mode of progression in smoldering multiple myeloma: a study of 406 patientsNadine H Abdallah, Arjun Lakshman, Shaji K Kumar, et al.
British Journal of Haematology|June 23, 2016
Natural history of amyloidosis isolated to fat and bone marrow aspirateRajshekhar Chakraborty, Morie A Gertz, Angela Dispenzieri, et al.
The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Bone Marrow Transplantation|April 11, 2017
Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survivalN Tandon, E Muchtar, S Sidana, et al.
Leukemia|October 22, 2015
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myelomaG P Kaufman, M A Gertz, A Dispenzieri, et al.
Mayo Clinic Proceedings|February 7, 2021
Coagulation Abnormalities in Light Chain AmyloidosisNadine Abdallah, Eli Muchtar, Angela Dispenzieri, et al.
Kidney International|April 4, 2008
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chainsN Leung, M A Gertz, S R Zeldenrust, et al.
Bone Marrow Transplantation|November 5, 2013
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapyS K Kumar, J Mikhael, B Laplant, et al.
Pageof 45

Showing results (211-220 of 446) with videos related to

Sort By:
Pageof 45
American Journal of Hematology|July 28, 2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapiesNeil Majithia, S Vincent Rajkumar, Martha Q Lacy, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Blood Cancer Journal|January 16, 2024
Mode of progression in smoldering multiple myeloma: a study of 406 patientsNadine H Abdallah, Arjun Lakshman, Shaji K Kumar, et al.
British Journal of Haematology|June 23, 2016
Natural history of amyloidosis isolated to fat and bone marrow aspirateRajshekhar Chakraborty, Morie A Gertz, Angela Dispenzieri, et al.
The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Bone Marrow Transplantation|April 11, 2017
Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survivalN Tandon, E Muchtar, S Sidana, et al.
Leukemia|October 22, 2015
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myelomaG P Kaufman, M A Gertz, A Dispenzieri, et al.
Mayo Clinic Proceedings|February 7, 2021
Coagulation Abnormalities in Light Chain AmyloidosisNadine Abdallah, Eli Muchtar, Angela Dispenzieri, et al.
Kidney International|April 4, 2008
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chainsN Leung, M A Gertz, S R Zeldenrust, et al.
Bone Marrow Transplantation|November 5, 2013
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapyS K Kumar, J Mikhael, B Laplant, et al.
Pageof 45